Regulatory shift could alter biosimilars business case
Pharmaceutical companies should look afresh at the business case for investing in ‘candidate’ biosimilars amidst signs that the cost of bringing those products to market globally could be about to significantly reduce owing to an apparent shift in regulatory approach.
